#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This study highlights a significant gap between cancer survivors’ interest in cannabis for symptom management and healthcare providers’ willingness to discuss or recommend it, which may leave patients without evidence-based guidance on a potential therapeutic option. Clinicians need awareness of these divergent perspectives to engage in informed shared decision-making about cannabis use, particularly as an adjunct to opioid therapy for cancer-related pain and chemotherapy side effects. Understanding patient demand for cannabis information allows providers to develop competency in discussing risks, benefits, and quality/safety concerns rather than defaulting to avoidance or dismissal.
A Virginia Commonwealth University study revealed significant disagreement between cancer survivors and their healthcare providers regarding medical cannabis use for symptom management, highlighting an important communication gap in oncology practice. Cancer patients experiencing pain, nausea, and other treatment-related symptoms expressed greater interest in and openness toward cannabis as an alternative or adjunctive therapy compared to their oncologists, who voiced more concerns about efficacy, safety, and regulatory status. This divergence is particularly relevant given the opioid crisis context in which many clinicians and patients are seeking non-opioid options for cancer-related symptoms, yet lack alignment on cannabis as a potential solution. The findings suggest that oncologists may be underestimating their patients’ desire for cannabis information and may not be routinely discussing this option despite growing patient interest. Clinicians should consider initiating frank, evidence-based discussions with cancer patients about cannabis, including realistic expectations about symptom relief, potential drug interactions, and legal considerations in their state, to ensure shared decision-making rather than leaving patients to pursue cannabis outside the clinical relationship.
“This observational study highlights a real communication gap between patients and providers around cannabis use in cancer care, which is worth taking seriously, but we need to recognize that surveyed opinions don’t tell us about actual clinical outcomes or safety profiles in this population. I’d want to see this prompt further investigation into prospective data on efficacy and drug interactions before we draw firm conclusions about medical cannabis as an opioid alternative for cancer survivors.”
💊 While cancer survivors increasingly turn to medical cannabis for symptom management—particularly for pain, nausea, and anxiety—this VCU study highlights a concerning disconnect between patient preferences and provider perspectives that warrants attention in clinical practice. Providers may hesitate to recommend or discuss cannabis due to limited clinical evidence, regulatory uncertainty, and concerns about drug interactions or dependence, whereas survivors often report meaningful symptom relief and prefer cannabis as an opioid alternative. This divergence is complicated by heterogeneous product formulations, variable cannabinoid concentrations, and a dearth of rigorous trials in oncology populations, making it difficult to establish clear clinical guidance. Oncologists and supportive care teams should recognize that dismissing patient interest in cannabis without substantive discussion may erode trust and drive patients toward unregulated sources or unsupervised use. A practical step forward is to adopt a more informed curiosity about cannabis in cancer care: routinely
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
